Objective: The incidence of radiation-induced late xerostomia varies greatly in nasopharyngeal carcinoma patients treated with radiotherapy. The single-nucleotide polymorphisms in genes involved in DNA repair and fibroblast proliferation may be correlated with such variability. The purpose of this paper was to evaluate the association between the risk of developing radiationinduced late xerostomia and four genetic polymorphisms: TGFb1 C-509T, TGFb1 T869C, XRCC3 722C.T and ATM 5557G.A in nasopharyngeal carcinoma patients treated with Intensity Modulation Radiated Therapy. Methods: The severity of late xerostomia was assessed using a patient self-reported validated xerostomia questionnaire. Polymerase chain reaction-ligation detection reaction methods were performed to determine individual genetic polymorphism. The development of radiationinduced xerostomia associated with genetic polymorphisms was modeled using Cox proportional hazards, accounting for equivalent uniform dose. Results: A total of 43 (41.7%) patients experienced radiation-induced late xerostomia. Univariate Cox proportional hazard analyses showed a higher risk of late xerostomia for patients with XRCC3 722 TT/CT alleles. In multivariate analysis adjusted for clinical and dosimetric factors, XRCC3 722C.T polymorphisms remained a significant factor for higher risk of late xerostomia. Conclusions: To our knowledge, this is the first study that demonstrated an association between genetic polymorphisms and the risk of radiation-induced late xerostomia in nasopharyngeal carcinoma patients treated with Intensity Modulation Radiated Therapy. Our findings suggest that the polymorphisms in XRCC3 are significantly associated with the risk of developing radiation-induced late xerostomia.
INTRODUCTION
Radiotherapy (RT) plays an important role in the treatment of nasopharyngeal carcinoma (NPC). Although NPC patients can be effectively treated with conventional RT, the long-term side effects of RT are highly prevalent and severely reduce the patient's quality of life (1) . Radiation-induced xerostomia is the most commonly reported complications during and after RT, which is caused by radiationinduced damage to the salivary glands. Lack of saliva can lead to multiple problems, including poor dental hygiene, a propensity for oral infection, oral pain and difficulty in chewing and swallowing (2) . Previous studies showed that the severity of the damage to the salivary glands was dependent on the total radiation dose and on the volume of irradiated tissue (3, 4) . Therefore, most of present studies focused on sparing the salivary glands from unnecessary irradiation by conformal radiation to reduce the risk of xerostomia. Randomized clinical trials showed that Intensity Modulation Radiated Therapy (IMRT) could reduce the severity of xerostomia compared with conventional radiation therapy by limiting the mean parotid gland dose to ,26 -30 Gray (Gy) (5, 6) . However, even with strictly following this criterion, 40% NPC patients still experienced late xerostomia. There is considerable inter-patient heterogeneity on the incidence of xerostomia, which cannot be fully illustrated by clinical and dosimetric factors.
It has been hypothesized that genetic factors may influence normal tissue radiosensitivity, especially genes responsible for the radiation-induced DNA damage signal and repair (7, 8) . Single-nucleotide polymorphisms (SNPs) in DNA repair genes may alter protein function and individual's capacity to repair damaged DNA, by which influence individual radiosensitivity and the risk of developing radiation-induced toxicities (9) . In current view, normal tissue reactions exhibited after RT were determined by a multifactorial trait resulted from the combined effects of clinical, tumor, treatment and genetic factors (10, 11) . Various studies examined the effects of candidate polymorphic genes involved in DNA repair (XRCC3 and ATM) and fibrogenesis (TGFb1) on the radiation-related toxicity. The gene variants of XRCC3, ATM and TGFb1 have been shown to be correlate with hypersensitivity to RT (12 -14) . However, no study had examined the correlation between polymorphisms and radiation-induced late xerostomia in NPC patients treated with IMRT.
We hypothesized polymorphisms in genes for regulating DNA repair and fibrogenesis might influence radiosensitivity of parotid glands and may account for the heterogeneity of xerostomia in NPC patients after IMRT. The aim of this study was to investigate the relationship between TGFb1 C-509T (rs1800469), TGFb1 T869C (rs1800470), XRCC3 722C.T (rs861539) and ATM 5557G.A (rs1801516) polymorphisms and the risk of radiation-related late xerostomia in NPC patients treated with IMRT.
PATIENTS AND METHODS

PATIENT SELECTION
The study included 106 patients with histopathologically confirmed NPC treated with IMRT between August 2002 and May 2008. All patients had documented dosimetric data as well as clinical and toxicity data within at least 2 years' follow-up. We excluded three patients with Sjogren syndrome, 'diabetes mellitus' or other autoimmune diseases, which might induce salivary gland acinar destruction. Finally, 103 patients were included in this study and signed informed consents. The patients were staged according to the AJCC Cancer staging Manual sixth edition for NPC. The study protocol was approved by the Ethics Committee of Hangzhou Cancer Hospital, Hangzhou, China.
TREATMENT AND FOLLOW-UP Simultaneous modulated accelerated RT technique was adopted in our center. The doses prescribed to gross target volume (GTV) and clinical target volume (CTV) were 2.5 and 2.0 Gy per fraction with a total dose of 70 and 60 Gy delivered in 28 fractions within 6 weeks, respectively. The delineation of GTV, CTV and dose-volume constraints of normal tissue was presented in our previous report (15) . All patients received IMRT as definitive treatment without concurrent chemotherapy. Patients with locally advanced disease received two cycles of neo-adjuvant chemotherapy containing cisplatin and taxol. As salivary production is largely (60 -70% of total) derived from the parotid glands, the radiation dose of parotid glands received was used to evaluate the effect of radiation on xerostomia. Equivalent uniform dose (EUD) was calculated to account for differences in fractionation, using the formula
where N represents the number of voxels in the target or organs at risk (OAR), D i is the dose in the ith voxel of the structure of interest and a is a tissue or tumor-specific parameter (16) . Through the a value, the EUD could reflect the biologic significance of a non-uniform dose distribution in the targets and the OARs. In the present study, the value of the parameter a for parotid gland was taken as 5 (17) . The severity of late xerostomia was assessed using a patient self-reported validated xerostomia questionnaire (XQ), which was developed by University of Michigan (18) . The summary score ranged between 0 and 100, with higher scores representing higher level of xerostomia. In this classification, no xerostomia was defined as the final XQ scores ranging from 0 to 10. Grade 1, 2 and 3 xerostomia were defined as the XQ scores ranging from 11 to 40, from 41 to 60 and from 71 to 100, respectively. Development of late xerostomia of Grade 1 was considered late toxicity of radiation in our study. After the completion of RT, patients were evaluated every 3 months for the first 2 years, every 6 months till 5 years and then once a year. The previous report showed that both the salivary flow rate and the XQ scores improved continuously throughout the first 2 years after RT (19) . Therefore, we evaluated the severity of radiation-induced late xerostomia at 2 years after RT.
SELECTION OF GENES AND POLYMORPHISMS
The selected polymorphisms are located in genes related to DNA repair mechanisms and fibroblast proliferation and differentiation. The XRCC3 and ATM genes were involved in the homologous recombination of the double-strand breaks
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XRCC3 and radiation-induced late xerostomia repair. TGFb1 was associated with radiation-induced fibrosis. The selection of these specific three genes for SNP screening was based on previous results indicating that these genes possess SNPs associated with the development of adverse effects after RT. The National Center for Biotechnology Information (NCBI) dbSNP ID of the four SNPS are listed as follows: TGFb1 C-509T (rs1800469), TGFb1 T869C (rs1800470), XRCC3 722C.T (rs861539) and ATM 5557G.A (rs1801516).
DNA EXTRACTION AND GENETIC SCREENING
Heparinized blood samples were collected before starting of RT. Genomic DNA used for polymerase chain reaction (PCR) amplification was extracted from lymphocytes separated from whole blood samples using a genomic DNA extraction kit (Promega, USA). PCR -ligation detection reaction (LDR) methods were used to perform the genotyping. The PCRs were performed on the ABI 9600 (Applied Biosystems, Foster City, CA, USA) in a total volume of 15 ml reaction system containing 1 ml genomic DNA, 1.5 mM of MgCl 2 , 0.3 ml dNTP (10 mM/ml), 0.5 ml of Taq DNA polymerase and 0.2 mM of each couple of primers. The PCR primers for the four genes were 5 0 -TTCCCTATCTGTAAATTGGG-3
0 (reverse) for ATM 5557G.A, respectively. The PCR protocol was defined by an initial denaturation step at 948C for 2 min, followed by 35 cycles of 948C for 20 s, 608C for 20 s and 728C for 40 s, with a final extension at 728C for 3 min. The LDR reaction was conducted with 3 ml PCR products, 1.0 ml of Taq DNA ligase buffer solution, 0.125 ml Taq DNA ligase and 0.12 ml LDR probe. The probe sequences were shown in Supplementary data, Table. The probes for LDR have common phosphorylated 5 0 -end and 6-carboxyXuorescein (FAM) labeled 3 0 -end. The LDR parameters were as follows: 20 cycles of 948C for 30 s, 608C for 3 min. The LDR reaction products were analyzed on an ABI 377 DNA Sequencer (Applied Biosystems) in the mixture containing 1ml LDR products, 1 ml loading buffer solution and 1 ml inside reference fluorescence. To verify the accuracy of PCR -LDR genotyping method, 10% of the samples were selected to perform by comparing each PCR product DNA sequence with previously published interested gene sequences available on the NCBI website. The results of the PCR -LDR genotyping showed 100% concordance to direct DNA sequencing of the randomly selected PCR products.
STATISTIC ANALYSES Each polymorphism was tested for deviation from HardyWeinberg equilibrium by comparing the observed and expected genotype frequencies using the x 2 test with 1 degree of freedom. We searched the database of the genotype distribution for each gene in Chinese normal population as control.
The x 2 test was used to compare the clinical characteristics and distribution of SNPs. Fisher's Exact test was used when the sample size was small (n , 5). Previous studies showed that the risk of developing of xerostomia increased with the radiation dose; (20) therefore, we modeled the occurrence of this event in relation to EUD received instead of time in days. The probability of not developing xerostomia was analyzed in relation to EUD using the Kaplan -Meier methods. Comparison of EUD curves was made using the log-rank test. The hazard ratios (HRs) with their corresponding 95% confidence intervals (CIs) were performed by Cox proportional hazard analyses to evaluate the influence of clinical factors and genotypes on the risk of developing radiation-induced late xerostomia. Multivariate Cox regression analysis was performed for other covariates. We divided polymorphisms of each gene into two groups according to whether it was a variant allele or not in multivariate analysis. All reported P values were two-sided, and P , 0.05 indicates statistical significance. All analyses were carried out using the SPSS 17.0 software package (SPSS Inc., Chicago, IL, USA). Table 2 .
ASSOCIATION BETWEEN RADIATION-INDUCED LATE XEROSTOMIA AND INDIVIDUAL SNPS
The distributions of XRCC3 722C.T, TGFb1 C-509T and ATM 5557G.A were in Hardy -Weinberg equilibrium. The P value was 0.11, 0.99 and 0.92 for XRCC3 722C.T, TGFb1 C-509T and ATM 5557G.A, respectively. TGFb1 T869C was disequilibrium in the test (P , 0.001). After consulting statistician, we excluded TGFb1 T869C in further analysis, as the results on TGFb1 T869C may be unreliable. The distributions of SNPs in this study and Chinese normal population were summarized in Table 3 The association of genotypes with xerostomia is listed in Table 4 . The results showed that the XRCC3 722C.T polymorphism was associated with the presence of late xerostomia (P ¼ 0.021). None of the remaining SNPs was significantly correlated with the occurrence of late xerostomia. The result of Kaplan -Meier analysis with log-rank test showed that carriers of XRCC3 722 CC genotypes were associated with a significantly increased risk of developing of late xerostomia (HR ¼ 2.885, 95% CI ¼ 1.267 -6.568, P ¼ 0.007, Fig. 1 ). However, the variants of TGFb1 C-509T (HR ¼ 0.999, 95% CI ¼ 0.442 -2.257, P ¼ 0.998, Fig. 2 ) were not associated with the risk of late xerostomia.
Univariate Cox proportional hazard analyses showed a higher risk of late xerostomia for patients with XRCC3 722 TT/CT alleles (HR ¼ 2.295, 95% CI ¼ 1.007 -5.229, P ¼ 0.047). After a multivariate adjustment for clinical factors including age, sex, tumor histology, T stage and application of 
DISCUSSION
In this study, we analyzed the association of genetic polymorphisms in TGFb1, XRCC3 and ATM with the development of radiation-induced late xerostomia in NPC patients treated with IMRT. Our findings suggested that the risk of radiation-induced late xerostomia was significantly increased in carriers of variants of XRCC3 722 C.T. Analysis of EUD with the probability of not developing xerostomia showed that patients with CT/TT genotypes in XRCC3 722 C.T was associated with a higher risk of developing radiation-induced late xerostomia than those with CC genotypes. To our knowledge, this is the first study that indicated an association between genetic polymorphisms and the risk of radiation-induced late xerostomia in NPC patients treated with IMRT. The result reported in this study supported that possession of SNPs associated with radiosensitivity correlated with an increased probability of developing of radiation-induced late xerostomia.
In terms of variant alleles, the genotype distributions of XRCC3 722C.T, TGFb1 C-509T and ATM 5557G.A were in line with those in the Chinese normal population (P . 0.05). However, the genotype distribution of TGFb1 T869C was significantly different from that in Chinese normal population (P , 0.001). The genotype distribution of TGFb1, XRCC3 and ATM frequencies of XRCC3 722C.T (0.09 in (24) (25) (26) . Such a phenomenon may be resulted from racial difference. XRCC3 gene, a member of Rad-51-related genes, is responsible for the homologous recombination of DNA doublestrand break repair and interstrand cross-links, which plays an important role in maintaining genome stability (27) . Functional date suggested that the presence of the polymorphism in XRCC3 might be associated with slightly decreased DNA repair capacity. The variants of XRCC3 may lead to defect capacity to repair damaged DNA and result in an elevated cancer risk (28) . Lee et al. (29) reported that the variants of XRCC3 were associated with increased risk of developing breast cancer. Many studies also found a positive relationship between the polymorphisms of XRCC3 and an increased risk of various cancers, including cancers of skin, lung, bladder, ovary, leukemia, head and neck and brain (30) .
XRCC3 polymorphisms have also been extensively tested for its association with radiation side effects in a variety of cancers. Most studies failed to find any significant correlation between the 722 C.T variants and the risk of radiationinduced acute complications. However, several studies reported that the variants of XRCC3 were associated with radiation-induced late toxicity. De Ruyck et al. (31) studied the XRCC3 polymorphisms in the samples of cervical cancer and concluded that SNPs in XRCC3 are associated with an increased risk of late toxic effect after radiation. Andreassen et al. (32) reported that the polymorphism in XRCC3 correlated with increased risk of subcutaneous fibrosis as well as telangiectasia in breast cancer. Damaraju et al. confirmed that there were significant univariate associations between late rectal or bladder toxicity and XRCC3 SNPs (33, 34) . Our results are in line with previous reports showing an association of XRCC3 722 C.T allele with an increased risk of radiation-induced late xerostomia. However, many studies failed to note associations between SNPs in XRCC3 with late toxicity resulting from RT. The risk of allele analysis results was still inconclusive.
On the other hand, our study failed to show the association between TGFb1 C-509T, ATM 5557 G.A and radiationinduced late xerostomia. TGFb1 is a multifunctional growth factor regulating cell proliferation, tissue differentiation, inflammation and fibrosis. Conflicting results have been reported on the impact of TGFb1 C-509T polymorphisms on normal tissue radiosensitivity, and either an increased risk or a lack of association has been reported for both variants (31, 35) . It was reported that genetic polymorphisms in the ATM gene were associated with late toxicity in cancer patients treated with RT (25) . However, our data showed that only two NPC patients experienced ATM (5557G.A) polymorphism. We could not get definitive conclusion depending on such low frequencies of variant alleles of ATM 5557G.A.
With the use of IMRT, the treatment plan can ensure delivery of the highest dose to the target area while sparing the surrounding normal tissues. However, there were still large volumes of normal tissue exposed to low-dose radiation. What is more, there are an increasing number of patients with locally advanced disease using systematic chemotherapy, which resulted in a significant reduction of the risk of death. However, such improvements are accompanied by increased radiation-induced toxicity (3) . In this regard, the study of SNPs appears to be important for clinical practice of RT, which may help to identify individuals at high risk of acute or 
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XRCC3 and radiation-induced late xerostomia late toxicity and in turn allows designing a personalized treatment schedule to reduce the toxic effects. One aim of SNPs studies is to develop tools for biologically individualized RT by taking into consideration of the individual risk of developing radiation-induced morbidity. Another aim is to improve the ability to reduce the morbidity, through prevention or intervention.
LIMITATIONS OF THIS STUDY
Our findings should be interpreted in the light of the following limitations. First, our study selected the mean parotid dose to analysis the dosimetric dose-volume parameters between xreostomia and radiation, neglecting the contribution of salivary production from the submandibular and sublingual glands and numerous small oral salivary glands. Saarilahti et al. reported that submandibular gland sparing could reduce the risk of both stimulated and unstimulated xerostomia. The mean dose to the oral cavity (containing small oral salivary glands) has been found to be an independent risk factor in some data sets but not others. Secondly, we cannot exclude the possibility that there may still have been inter-patients variability in the evaluation of the degree of late xerostomia in the present study. Thirdly, the number of patients recruited was small. Thus, additional studies including larger numbers of patients or a systematic review are necessary to confirm our findings. What is more, further investigations based on a larger number of candidate polymorphic genes are strongly warranted for more comprehensive identification of a clinically useful SNP profile that can identify patients at greater risk of the development of radiation injury.
In conclusion, we found that NPC patients with the variant alleles of XRCC3 c.722 C.T gene were more likely to experience radiation-induced late xerostomia. We hypothesized that the genetic polymorphisms may be promising candidates for predicting radiation toxicity of normal tissue, but further studies are necessary to confirm our findings.
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